Active Ingredient History
Ixabepilone is an antineoplastic agent, epothilone and mitotic inhibitor that is FDA approved for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Ixabepilone binds directly to beta-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of alpha-beta-II and alpha-beta-III microtubules. The most common adverse reactions (≥20%) are peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, and musculoskeletal pain. Inhibitors of CYP3A4 may increase plasma concentrations of ixabepilone. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Astrocytoma (Phase 1/Phase 2)
Bile Duct Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 3)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Genital Diseases, Male (Phase 2)
Genital Neoplasms, Male (Phase 2)
Glioblastoma (Phase 1/Phase 2)
Gliosarcoma (Phase 1/Phase 2)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1/Phase 2)
Intestinal Neoplasms (Phase 1)
Kidney Neoplasms (Phase 1)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Melanoma (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms, Glandular and Epithelial (Phase 2)
Neuroblastoma (Phase 2)
Neutropenia (Phase 1)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pain (Phase 3)
Pancreatic Neoplasms (Phase 2)
Peripheral Nerve Injuries (Phase 3)
Prostatic Diseases (Phase 2)
Prostatic Neoplasms (Phase 2)
Rhabdomyosarcoma (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Testicular Neoplasms (Phase 2)
Tongue Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Urogenital Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Wilms Tumor (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
